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INTRODUCTION
It has long been recognized that breast cancers can invade
and grow as metastases in bone (1). Some breast cancer cell
lines induce osteolytic lesions in animal models that mimic
the metastatic process in clinical breast cancer (2, 3), but the
factors favoring the growth of breast cancer in bone remain to
be resolved. Bone destruction is primarily mediated by osteo-
clastic bone resorption (4), and cancer cells that have metasta-
sized to bone stimulate the formation and activation of osteo-
clasts next to metastatic foci (5). Recent research has identified
several factors inducing osteoclast formation (4). If different
types of metastatic cancer follow the same mechanism to cause
osteolytic lesions, we may focus on this target to control and
prevent the damage to bone.
Accumulating evidences indicate that receptor activator of
NF-kB ligand (RANKL), also known as osteoclast differenti-
ation factor, is the ultimate extracellular mediator that acts on
osteoclast precursors to differentiate them into mature osteo-
clasts in the presence of macrophage-colony stimulating fac-
tor (M-CSF) (6, 7), and that many bone resorbing factors
up-regulate RANKL expression in bone marrow stromal and
osteoblastic cells (6, 8). Osteoprotegerin (OPG), also known
as osteoclastogenesis inhibitory factor, inhibits osteoclast devel-
opment (9, 10) because it is a decoy receptor for RANKL to
block its actions (6, 7). Thus, divergent mechanisms for bone
resorption may converge to the regulation of RANKL activi-
ties. Cancer cells induce formation of osteoclasts by secreting
osteotropic cytokines, such as PTH-related protein (PTHrP)
(11), interleukin-11 (IL-11) (12) and leukemia inhibitory fac-
tor (LIF) (13), or by direct contact with bone marrow cells
(1). The molecular mechanisms for the latter are yet unclear,
although osteotropic factors secreted by cancer cells could
induce RANKL. In order to reveal a mechanism for cancer-
induced osteoclastogenesis, we examined RANKL and OPG
expression in co-cultures of bone marrow stromal or osteoblas-
tic cells with breast cancer cells inducing osteoclast-like cell
formation in vitro.
MATERIALS AND METHODS
Tissue specimens and animals
Thirty tissue specimens from breast cancer were obtained
from thirty patients by surgical resection in KangDong Sacred
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Expression  of  Osteoprotegerin  and  RANK  Ligand  in  Breast  Cancer
Bone Metastasis
Bone destruction is primarily mediated by osteoclastic bone resorption, and cancer
cells stimulate the formation and activation of osteoclasts next to metastatic foci. Accu-
mulating evidences indicate that receptor activator of NF-kB ligand (RANKL) is the
ultimate extracellular mediator that stimulates osteoclast differentiation into mature
osteoclasts. In contrast, osteoprotegerin (OPG) inhibits osteoclast development. In
order to elucidate a mechanism for cancer-induced osteoclastogenesis, cells from
a human breast cancer line, MDA-MB-231, were directly co-cultured with ST2, MC3T3-
E1, or with primary mouse calvarial cells. Osteoclast-like cells and tartarate resistant
acid phosphatase (TRAP) activities were then quantitated. We examined these cell
lines and samples from breast cancer by RT-PCR for the expressions of OPG and
RANKL mRNA. Compared to controls, co-culture of MDA-MB-231 cells with stromal
or osteoblastic cells induced an increase in number of osteoclasts and TRAP activi-
ties. MDA-MB-231 cells alone or breast cancer samples did not express RANKL
mRNA. However, co-culture of these cancer cells with stromal or osteoblastic cells
induced RANKL mRNA expression and decreased OPG mRNA expression. These
experiments demonstrate that direct interactions between breast cancer and stromal
or osteoblastic cells induce osteoclastogenesis in vitro through modulating RANKL
expression.
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Heart Hospital, Hallym University Medical Center (Seoul,
Korea). Tissue specimens were snap-frozen in liquid N2 and
stored at -70℃until used. Male C57 black mice (6 weeks old)
were obtained from Asan Institute for Life Science (Seoul,
Korea). All procedures involving animals were approved by
the institutional animal care committee.
Isolation and culture of neonatal mouse calvarial cells
Calvariae from 3 to 5-day-old neonatal C57 black mice were
dissected and cut into small pieces. Following serial treatments
with 0.1% collagenase (Sigma, St. Louis, MO, U.S.A.) and
0.2% protease (Sigma, St. Louis, MO, U.S.A.), cells were col-
lected from the supernatant (fractions 2 to 5). Cells were cul-
tured in  -MEM (minimum essential media, GIBCO, Gai-
thersburg, MD, U.S.A.) supplemented with 10% FCS (fetal
calf serum, GIBCO, Gaithersburg, MD, U.S.A.), 100 IU/ L
penicillin and 100  g/ L streptomycin (GIBCO, Gaithers-
burg, MD, U.S.A.), at 37℃in a humidified atmosphere with
5% CO2. In addition, mouse osteoblastic cell line MC3T3-E1
and bone marrow-derived stromal cell line ST2 were used as
osteoblastic and stromal cells.
MDA-MB-231: a human breast cancer cell line
The MDA-MB-231 cell line was provided by the Korean
Cell Line Bank (Seoul, Korea). Cells were cultured in RPMI
(GIBCO, Gaithersburg, MD, U.S.A.) supplemented with 10%
FCS, 100 IU/ L penicillin, and 100  g/ L streptomycin (Life
Technologies, Inc.) at 37℃in a humidified atmosphere with
5% CO2. MDA-MB-231 cells were studied in co-culture sys-
tems with mouse bone marrow stromal or osteoblastic cells.
As described previously (12), 2×105 cancer cells were inoc-
ulated onto a 60 mm culture dish at 2 hr before seeding with
bone marrow stromal or osteoblastic cells, prepared as described
below. Serum-free conditioned media collected from the cul-
tures after a 5-day incubation were kept at -20°C until re-
quired. Aliquots of conditioned media were diluted with -
MEM supplemented with 10% FCS and used at dilutions of
1:2 and 1:5.
Mouse bone marrow culture for osteoclast formation
Bone marrow cells of 6-week-old male C57 black mice were
obtained from femora and tibiae, and were cultured as previ-
ously described (14). Non-adherent marrow mononuclear cells
were prepared and then re-suspended in -MEM supplement-
ed with 10% FCS at 106 cells/ L. Cells were plated in 96 well
plates (1×106 cells/well) to test the effects of conditioned me-
dia on the formation of osteoclasts. Cultures were maintained
in a humidified atmosphere of 5% CO2 at 37℃ for 8 days.
Cultures were fed once in every other day by removing half of
the medium and replacing it with an equal volume of fresh
medium.
Tartarate-resistant acid phosphatase (TRAP) staining
On the eighth day of bone marrow culture, cells were fixed
in 10% formalin neutral buffer solution for 10 min and stained
with an Acid Phosphatase Leukocyte Kit (Sigma Diagnostics,
St. Louis, MO, U.S.A.) for 1 hr at 37℃. TRAP-positive multi-
nucleated cells with more than three nuclei per well were
counted.
TRAP activity
For TRAP activities, 100  L of culture media were mixed
with 100  L of 0.2 M sodium acetate buffer, 16  L of 0.1 M
pNPP, and 4  L of 2.0 M L(+) tartarate for 1 hr at 37℃. We
added 16  L of 0.5 M NaOH and measured the optical density
at 405 nm, using an ELISA plate reader.
RT-PCR for OPG and RANKL mRNA expression
Adherent bone marrow cells (2×105/60 mm dish) were co-
cultured with or without cancer cells (2×105/60 mm dish)
as described above. After 5 days, total RNAs were extracted
by using RNeasy Kits (Qiagen, Santa Clarita, CA, U.S.A.) and
then reversely transcribed according to the instructions of the
manufacturer. Total RNAs from thirty tissue specimens of
breast cancer were also extracted by using the same kits. Primer
sequences (Bioneer, Korea): OPG, 5′ -AACCCCAGAGCGAA-
ACAC-3′ (sense), 5′ -AAGAAGGCCTCTTCACAC-3′ (anti-
sense), RANKL, 5′ -GGTCGGGCAATTCTGAATT-3′
(sense), and 5′ -GGGGAATTACAAAGTGC-3′ (antisense).
PCR was performed on a 9600 thermal cycler (Perkin Elmer,
Norwalk, CT, U.S.A.), at the following conditions: at 94℃
for 1 min (1 cycle), at 55℃for 40 sec, and at 72℃for 1 min
(32 cycles) for OPG; at 94℃ for 1 min (1 cycle), at 62℃ for
1 min, and at 72℃ for 1 min (32 cycles) for RANKL. For
semi-quantitative RT-PCR, one  g of total RNA was treated
with DNase I, reversely transcribed, and subjected to PCR for
OPG and RANKL. Mouse  -actin mRNA expression was
also examined by RT-PCR as an internal control.
Statistical analysis
All the experiments were repeated at least three times. Data
were expressed as mean±SE and analyzed by one-way analy-
sis of variance. An unadjusted p value of less than 0.05 was
considered to be significant.
RESULTS
Cancer cells adhered to bone marrow cells induce
formation of TRAP-positive multinucleated cells
Direct co-cultures of mouse bone marrow cells with MDA-OPG and RANKL in Breast Cancer 543
MB-231 cells, without osteotropic agents, generated some
TRAP-positive multinucleated cells.
MDA-MB-231 conditioned medium increases the for-
mation of osteoclasts in mouse bone marrow cultures
To test the effects of the factor (s) released from the tumor cells
on the formation of osteoclasts, bone marrow cells were cul-
tured either in the presence or the absence of MDA-MB-231
conditioned medium from co-culture with osteoblastic (MC-
3T3-E1) or stromal (ST-2) cells. The use of conditioned medi-
um, even at the highest dilution (1:5), significantly increased
the number of TRAP (+) multinucleated cells. The mean
number of TRAP (+) multinucleated cells/field was 16.4 in
treated cultures, compared with 8.6 in controls (Fig. 1). TRAP
activities were also significantly increased with the addition
of the conditioned media from co-culture (Fig. 2).
Co-culture of cancer cells with bone marrow cells
induces RANKL expression
In order to clarify the mechanism whereby cancer cells induce
osteoclast-like, TRAP-positive multinucleated cell to form in
vitro through their direct contact with bone marrow cells, we
examined the expression of RANKL mRNA by RT-PCR.
Cancer cell lines or tissue specimens from breast cancer did
not express RANKL mRNA. Co-cultures of MDA-MB-231
with osteoblastic (MC3T3-E1) or stromal (ST-2) cells induced
the RANKL mRNA expression (Fig. 3).
Co-culture of cancer cells with bone marrow cells
reduces OPG expression
Osteoblastic (MC3T3-E1) or stromal (ST-2) cells alone exp-
ressed OPG. Co-culture of MDA-MB-231 cells with osteo-
blastic (MC3T3-E1) or stromal (ST-2) cells reduced the expres-


















































Fig. 1. Effects of conditioned media on osteoclast generation in
bone marrow cultures. Conditioned media from co-culture of MDA-
231 with ST2 or MC3T3-E1 cells increase TRAP-positive multinu-




































Fig. 2 . Effects of conditioned media on TRAP activity in bone mar-
row cultures. Conditioned media from co-culture of MDA-231 with

























































Fig. 3. Expression of RANKL mRNA assessed by RT-PCR. The re-
sults were shown as a ratio of RANKL to actin mRNA. Co-culture of












































Fig. 4. Expression of OPG mRNA assessed by RT-PCR. Co-culture
of MDA-231 with ST2 or MC3T3-E1 cells inhibit expression of OPG
mRNA. 544 H.-R. Park, S.-K. Min, H.-D. Cho, et al.
DISCUSSION
Breast cancers commonly cause osteolytic metastases in bone,
a process that depends upon osteoclast-mediated bone resorp-
tion, but the mechanism of osteoclast activation is not yet clear.
In the present study we assessed whether a well-known human
breast cancer cell line (MDA-MB-231) could cause osteoclasts
to form in mouse bone marrow cultures. This cell line increases
osteoclast formation in vitro and forms osteolytic bone metas-
tases in mice (6). We demonstrated that in bone marrow cul-
tures, the conditioned medium harvested from MDA-MB-231
increased the formation of multinucleated TRAP-positive cells.
These data suggest that MDA-MB-231 produces factors that
increase the formation of osteoclasts in bone marrow culture.
Teti et al. (4) observed that melanomas as well as breast car-
cinomas could induce osteoclast formation in vitro. Experi-
ments where bone marrow cells contacted tumor cells direct-
ly showed similar results to those where bone marrow cells
were incubated in serum-free media conditioned by tumor
cells. This effect was dose-dependent and indicated that cell-
cell contact was not required. Furthermore, similar effects
were observed whether the conditioned media were added to
the bone marrow cultures during the first 1-6 days or the last
6-10 days of osteoclast formation. Ono et al. (12) also exam-
ined mechanisms by which the breast cancer cell line, BALB/
c-MC, induces osteoclast formation. BALB/c-MC stimulated
osteoclast formation through direct contact with bone marrow
cells, and involved PGE2 released from bone marrow cells. Co-
culture of either mouse melanoma B16 cells or breast cancer
BALB/c-MC cells with mouse bone marrow cells induced
osteoclast-like cells, which were not observed when the cancer
cells were segregated from the bone marrow cells (10). Thus,
some tumor types seem to require direct contact with marrow
cells to induce osteoclast formation, whereas other tumor types
do not require direct contact.
When bone-seeking cancer cells stimulate osteoclast forma-
tion, the process involves several humoral factors, such as PTH-
rP (2), IL-11 (15), LIF (16), and PGE2 (12). However, since
the list was compiled from studies of several types of cancer
cells, these factors may not be universally used. Central to the
process is a group of TNF receptor and TNF ligand family
members. RANKL, also known as ODF, OPGL or TRANCE,
promotes osteoclast formation by interacting with the receptor
RANK, and the process is inhibited by the decoy receptor,
OPG (7, 17-22). It is now considered as a direct mediator of
many osteotropic factors (5). Our experiment revealed that
neither bone marrow stromal cells nor breast cancer cells alone
expressed RANKL mRNA. However, co-culture of these can-
cer cells with bone marrow stromal cells, or with osteoblastic
cells, induced RANKL expression. Moreover, when bone mar-
row stromal cells were co-cultured with cancer cells, the bone
marrow cells inhibited OPG. Thus, enhanced osteoclast for-
mation in the presence of cancer cells might be due to the
increase in RANKL activities. These results suggest that in
metastases where bone is damaged, interactions between can-
cer cells and bone marrow cells could induce RANKL and sup-
press OPG.
Overproduction of PTHrP by breast cancer cells may be im-
portant in determining their ability to establish and grow in
bone. Although Martin (7) found that breast cancers do not
produce RANKL themselves, they do produce PTHrP, and
this can influence bone cells to produce RANKL and decrease
OPG, thereby favoring osteoclast formation and metastasis
growth. Thomas et al. (11) determined that the breast cancer
cell lines MDA-MB-231, MCF-7, and T47D as well as prima-
ry breast cancers do not express RANKL but express OPG
and RANK. Because M-CSF and RANKL are essential for
osteoclast formation, Mancino et al. (6) hypothesized that
MDA-231 cells could stimulate osteoclastogenesis by produc-
ing one or both of these cytokines themselves or by stimulat-
ing bone marrow stromal/osteoblastic cells to produce them.
Soluble RANKL alone, or MDA-231 cells without added
RANKL did not support osteoclast formation from hematopoi-
etic cells. However, co-culture of MDA-231 cells with hema-
topoietic cells and added soluble RANKL stimulated signif-
icant osteoclast formation, indicating that MDA-231 cells
produce M-CSF. In contrast to their ability to produce M-
CSF, MDA-231 do not produce RANKL. However, when
co-cultured with the murine bone marrow stromal cell line
UAMS-33, MDA-231 cells increased their RANKL expres-
sion significantly. These results indicate that MDA-231 cells
could cause osteoclasts to form, partly by secreting M-CSF,
and partly by stimulating RANKL expression in host stro-
mal/ osteoblastic cells. IL-6 type cytokines may be involved
in stimulating RANKL expression.
Accumulating evidences indicate that RANKL produced by
bone marrow stromal cells is the final extracellular regulator
of osteoclast development. OPG is a soluble decoy receptor
for RANKL, and antagonizes its activities (20, 21). Thus, the
ratio of RANKL to OPG could regulate osteoclastogenesis.
When adherent bone marrow cells were studied, the presence
of MDA-MB-231 breast cancer cells significantly decreased
the concentration of OPG in culture media. This might incre-
ase the levels of free RANKL, enhancing osteoclast formation.
Because RANKL acts directly on hematopoietic osteoclast
precursors (20), observations shown here and by others suggest
that when cancer cells induce osteoclast development, it is
primarily by causing bone marrow cells to express RANKL.
Therefore, RANKL and OPG may be useful targets for treat-
ing bone metastases.
To elucidate the mechanism of osteoclastogenesis and bone
destruction in a mouse model of breast cancer, Kitazawa et al.
(5) used in situ hybridization to study the expression of RAN-
KL mRNA. In early stages of bone invasion, spindle-shaped
mesenchymal cells and osteoblasts on the bone surface expre-
ssed RANKL. At this stage, TRAP-positive osteoclasts were
already seen next to cancer cells. Cancer cells did not express
RANKL but did express PTHrP. At a later stage, when cancercells had invaded and started to damage the bone, RANKL
mRNA was detected mainly on the osteoblastic cells around
the eroded bone surface. TRAP-positive osteoclasts at the same
surfaces also expressed RANKL. Prior to direct invasion by
the cancer cells, RANKL expression was confined to the osteo-
blastic cell lineage, suggesting that cancer-derived factors like
PTHrP plays a central role in inducing RANKL, eventually
leading to bone destruction. The activities of OPG were stud-
ied in a syngeneic tumor model of humoral hypercalcemia of
malignancy. OPG blocked tumor-induced increases in bone
resorption and hypercalcemia and rapidly normalized blood
calcium. In tumor-bearing mice, OPG treatments reduced
osteoclast activities. The potent effects of OPG in this model
suggest it could be used therapeutically (13).
In conclusion, cell-cell interaction between cancer and bone
marrow cells possibly stimulates osteoclast-like cell formation
by inducing RANKL expression and suppressing OPG secre-
tion. This mechanism may be ubiquitous in bone destruction
in malignancy because in different tumor types, the actions
converge of RANKL. In addition, characterization of this sim-
ple model of tumor-induced osteoclast generation identified
possible molecular targets for treating osteolytic metastases.
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